Back to Search
Start Over
Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy".
- Source :
- Gastric Cancer; Nov2022, Vol. 25 Issue 6, p1133-1135, 3p
- Publication Year :
- 2022
-
Abstract
- We thank Professor Torlakovic for her comments and interest in our recent work on the concordance of PD-L1 assays in gastric cancer (GC) [[1]]. ImmunoAtlas: ATLA-220323-1: Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy: report information [cited 2022 September 13]. [Extracted from the article]
- Subjects :
- STOMACH cancer
PROGRAMMED death-ligand 1
IMMUNOHISTOCHEMISTRY
IMMUNOTHERAPY
Subjects
Details
- Language :
- English
- ISSN :
- 14363291
- Volume :
- 25
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Gastric Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 159817520
- Full Text :
- https://doi.org/10.1007/s10120-022-01343-4